GET TOP RATED STOCK ALERTS ACTIVE TRADERS DEPEND ON
SIGN UP TODAY FOR FREE NEWS DRIVEN ALERTS
Dallas, TX– May 2, 2019 – Kali-Extracts, Inc. (OTCPK: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) (“KALY”) today announced the all new HempTantation, a hemp derived CBD infused sunscreen. KALY has a U.S. Patented cannabis extraction process. The company is conducting ongoing research and development with its cannabis extracts to develop a variety of pharmaceutical treatments for a range of health conditions to include pain management, various lung diseases and type 2 diabetes. At the same time the company is developing and launching its own line of wellness and cosmetic products as well as partnering with other companies to produce additional wellness and cosmetic products. KALY currently sells Hemp4mula CBD infused gum and has licensed its patented cannabis extraction process to Puration, Inc. (USOTC: PURA) (“PURA”) for the production of EVERx CBD Sports Water. PURA’s infusion and bottling experience and capacity has been instrumental in KALY’s development of HempTantation. KALY’s Hemp4mula CBD infused gum and PURA’s EVERx CBD Sports Water are both available for sale now online from the North American Cannabis Holdings (USOTC: USMJ) (“USMJ”) Ecommerce site, USMJ.com. HempTantation is scheduled to be available for sale this summer from USMJ.com in addition to other online and brick and mortar retail outlets. Look for a HempTantation product launch announcement coming soon.
KALY is targeting the $17 billion global sun protection product market. In informal, non-medical, trials of KALY’s CBD infused lotion, users have reported the CBD formula has proven effective not only for protection from the sun, but relief and repair from sunburn.
The HempTantation product name has been developed in conjunction with a marketing campaign designed to rapidly establish brand recognition. Look for more details on the marketing campaign when KALY announces the official HempTantaion product launch.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
SOURCE: Kali-Extracts, Inc.
Dallas, TX – March 21, 2019 – Kali-Extracts, Inc. (OTC: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) (“KALY”) today published the research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY’s patented cannabis extraction process. The report details the study method and the significance of the study. The report includes specific findings and due to the substantial findings, the report includes guidelines for next stage tests.
“These preliminary studies were designed to begin assessment of the relative efficacy of NCMB-1 compound on pulmonary of in the AGM previously treated to induce a fixed level of airway fibrosis. The overall results demonstrate that NCMB-1 improved airway function as measured by increased tidal volume, increased airway flow and hence decreased airway resistance and increased respiration rate.”
“Given the in vitro studies previously conducted in cultured human pulmonary epithelial cells, the role of anti-inflammatory agents and their genetic regulation are a clear target for the continued study of the AGM and pulmonary functional responses to NCMB-1.”
The full report can be read on the company’s website at www.kali-extracts.com.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Source: Kali-Extracts, Inc.
Dallas, TX – December 10, 2018 – Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) today announced a $300,000 contract with Puration, Inc. (USOTC: PURA) (“PURA”) to produce custom hemp-derived CBD extracts. Kali-Extracts recently acquired a patented cannabis extraction process, that comes with a substantial volume of associated clinical research, in a reverse merger transaction with NCM Biotech. Kali-Extracts is accordingly in the process of rapidly updating the company’s public filings with OTCMarkets to both post the legacy operations past-due filings and to reflect the current cannabis extraction business. Kali-Extracts has a new website (www.kali-exracts.com) that includes a presentation of the company’s new cannabis extraction business plan. Now, less than one month after the reverse merger transaction, where Kali-Extracts acquired the patented cannabis extraction process, the company has signed its first revenue producing contract.
“With the legalization of hemp farming on the near horizon as drafted into the pending 2018 Farm Act, the flood gates are about to open for Kali-Extracts,” Said Frederick Ferri, the founder of NCM Biotech, and the incoming CEO of Kali-Extracts. “I am already receiving daily inquiries to formulate custom hemp-derived CBD extractions. The pending legalization of hemp farming, combined with the recent DEA removal of CBD from schedule 1, is igniting the commercialization of hemp-derived CBD concentrates for a multitude of applications from pharmaceutical to sports nutrition to over the counter pain management to general health and wellness.”
Kali-Extracts Partnership with Puration, Inc.
Kali-Extracts and Puraiton, Inc. have a long-term partnership that predates the reverse merger of NCM Biotech into Kali-Extracts. Puration has the sole license of the Kali-Extracts patented cannabis extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” In conjunction with Puration’s industry specific license, Puration currently produces EVERx CBD Sports Water, the leading CBD infused water in the sports nutrition market. Puration has trailing twelve-month revenues of approximately $1 million. More recently, Kali-Extracts and Puration, with two other partners, have together formed a joint venture company (JV) titled US Cannabis Health. The purpose of the JV is to pursue partnerships with pharmaceutical companies to produce cannabis extract pharmaceutical applications. The JV has recently signed its first agreement, and in conjunction with that agreement, Puration will produce private labeled hemp-derived CBD infused water under the client pharmaceutical company’s name. Puration has engaged Kali-Extracts to make a custom hemp-derived CBD extract specific to the requirements for the private labeled hemp-derived CBD water Puration will produce for the pharmaceutical company.
For more information visit:
and
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Puration, Inc.
Contact:
Puration, Inc.
Brian Shibley,
(800) 861-1350
Source: Kali, Inc.
Sign Up for FREE
Stock Alerts from
to be the first to know when this emerging company issues Breaking News!
About Kali, Inc.
Making lives better with cannabis therapies derived from our patented extraction process.
Pharmaceuticals
Dedicated to the research and development of cannabis treatments for various illnesses, diseases and chronic pain as a symptom of various diagnoses. Our unique patented extraction process results in the highest quality extracts. Because of this patented process, we are able to build a foundation of research through strategic partnerships.
Concentrates
Cannabis extracts are part of a healthy life style. Our extracts have already been proven in the health and wellness sector and ongoing research and development is targeted at improving on and expanding our current health and wellness products.
Kali Inc’s New Business Plan
With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the development of health and wellness therapies. The cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029. The cannabis concentrates for wellness, edibles and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022.
Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon.
Structure of the NCM Biotech Acquisition and Disposition of Legacy Assets
Kali issued a $1.5 million note in exchange for 100% of the issued and outstanding shares of NCM Biotech. In a related transaction, the majority shareholder voting control affected through preferred shares, was assigned to the NCM Biotech seller. No common shares of Kali were issued in the acquisition of NCM Biotech and Kali has no intention of executing either a reverse or forward split of Kali shares in conjunction with the acquisition of NCM Biotech. Kali financial reports are being updated as this presentation is drafted, and the filing of the necessary financial statements required to bring the company current are anticipated to be completed imminently.
Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated seventy five hundred dollars for Kali, Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Kali, Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.